AstraZeneca's Rezield Might Itself Be Saved By Sicker Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Members of FDA's Antiviral Drugs Advisory Committee say that MedImmune's RSV drug Rezield (motavizumab) doesn't pass the risk-benefit test for healthier patients, but it might for sicker patients.